Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...

NCT01118091 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

NIH

Sponsor class

Conditions

Skin Cancer
Melanoma
Metastatic Melanoma

Interventions

BIOLOGICAL: Aldesleukin
BIOLOGICAL: CD8 enriched Young TIL

Sponsor

National Cancer Institute (NCI)